Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Recall Regulations, 59633-59634 [E8-23910]
Download as PDF
Federal Register / Vol. 73, No. 197 / Thursday, October 9, 2008 / Notices
Estimated Total Annual Burden
Hours: 841.50.
In compliance with the requirements
of section 506(c)(2)(A) of the Paperwork
Reduction Act of 1995, the
Administration for Children and
Families is soliciting public comment
on the specific aspects of the
information collection described above.
Copies of the proposed collection of
information can be obtained and
comments may be forwarded by writing
to the Administration for Children and
Families, Office of Administration,
Office of Information Services, 370
L’Enfant Promenade, SW., Washington,
DC 20447, Attn: ACF Reports Clearance
Officer. E-mail address:
infocollection@acf.hhs.gov. All requests
should be identified by the title of the
information collection.
The Department specifically requests
comments on: (a) Whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
Dated: October 3, 2008.
Janean Chambers,
Reports Clearance Officer.
[FR Doc. E8–23884 Filed 10–8–08; 8:45 am]
Manufacturing Arrangements for
Licensed Biologics’’ has been approved
by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of Information
Management (HFA–710), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–796–3794.
SUPPLEMENTARY INFORMATION: In the
Federal Register of November 19, 2007
(72 FR 65034), the agency announced
that the proposed information collection
had been submitted to OMB for review
and clearance under 44 U.S.C. 3507. An
agency may not conduct or sponsor, and
a person is not required to respond to,
a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0629. The
approval expires on September 30,
2011. A copy of the supporting
statement for this information collection
is available on the Internet at https://
www.reginfo.gov/public/do/PRAMain.
Dated: September 29, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E8–23907 Filed 10–8–08; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–N–0314]
BILLING CODE 4184–01–P
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Recall Regulations
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
ACTION:
Food and Drug Administration
[Docket No. FDA–1999–D–0128] (formerly
Docket No. 1999D–2013)
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Guidance for Industry: Cooperative
Manufacturing Arrangements for
Licensed Biologics
AGENCY:
Food and Drug Administration,
sroberts on PROD1PC70 with NOTICES
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Guidance for Industry: Cooperative
VerDate Aug<31>2005
21:01 Oct 08, 2008
Jkt 217001
Food and Drug Administration,
HHS.
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by November
10, 2008.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974, or e-mailed to
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
59633
baguilar@omb.eop.gov. All comments
should be identified with the OMB
control number 0910–0249. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Elizabeth Berbakos, Office of
Information Management (HFA–710),
Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857,
301–796–3792.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
FDA Recall Regulations—21 CFR Part
7—(OMB Control Number 0910–0249—
Extension)
Section 701 of the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. 371) and
part 7, subpart C (21 CFR part 7, subpart
C), set forth the recall regulations
(guidelines) and provide guidance to
manufacturers on recall responsibilities.
The guidelines apply to all FDA
regulated products (i.e., food, including
animal feed; drugs, including animal
drugs; medical devices, including in
vitro diagnostic products; cosmetics;
and biological products intended for
human use). These responsibilities
include: (1) developing a recall strategy
that requires time by the firm to
determine the actions or procedures
required to manage the recall (§ 7.42);
(2) providing FDA with complete details
of the recall including reason(s) for the
removal or correction, risk evaluation,
quantity produced, distribution
information, firm’s recall strategy, a
copy of any recall communication(s),
and a contact official (§ 7.46); (3)
notifying direct accounts of the recall,
providing guidance regarding further
distribution, giving instructions as to
what to do with the product, providing
recipients with a ready means of
reporting to the recalling firm (§ 7.49);
(4) submitting periodic status reports so
that FDA may assess the progress of the
recall (status report information may be
determined by, among other things,
evaluation return reply cards,
effectiveness checks, and product
returns) (§ 7.53); and (5) providing the
opportunity for a firm to request in
writing that FDA terminate the recall
(§ 7.55).
A search of the FDA database was
performed to determine the number of
recalls that took place during fiscal year
2007. The resulting number of recalls
from this database search (2,166) is used
in estimating the current annual
reporting burden for this report. FDA
E:\FR\FM\09OCN1.SGM
09OCN1
59634
Federal Register / Vol. 73, No. 197 / Thursday, October 9, 2008 / Notices
estimates the total annual industry
burden to collect and provide the
previous information to 216,600 burden
hours.
Table 1 of this document is a
summary of the estimated annual
burden hours for recalling firms
(manufacturers, processors, and
distributors) to comply with the
voluntary reporting requirements of
FDA’s recall regulations.
In the Federal Register of June 3, 2008
(73 FR 31696), FDA published a 60-day
notice requesting public comment on
the information collection provisions.
No comments were received.
Recognizing that there may be a vast
difference in the information collection
and reporting time involved in different
recalls of FDA’s regulated products,
FDA estimates on average the burden of
collection for recall information to be as
follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
No. of
Respondents
21 CFR Section
Annual Frequency
per Response
Total Annual
Responses
Hours per
Response
Total Hours
Recall strategy 7.42
2,166
1
2,166
20
43,320
Firm initiated recall and recall communications 7.46 and 7.49
2,166
1
2,166
30
64,980
Recall status reports and followup
7.53
2,166
4
8,664
10
86,640
Termination of a recall 7.55(b)
2,166
1
2,166
10
21,660
Total
1 There
216,600
are no capital costs or operating and maintenance costs associated with this collection of information.
D. Termination of a Recall
Provide the firms an opportunity to
request in writing that FDA end the
recall. The agency estimates it will
receive 2,166 responses annually.
The annual reporting burdens are
explained as follows:
Reporting
A. Recall Strategy
Request firms develop a recall strategy
including provision for public warnings
and effectiveness checks. Under this
portion of the collection of information,
the agency estimates it will receive
2,166 responses annually.
B. Firm Initiated Recall and Recall
Communications
Request firms voluntarily remove or
correct foods and drugs (human or
animal), cosmetics, medical devices,
and biologicals to immediately notify
the appropriate FDA district office of
such actions. The firm is to provide
complete details of the recall reason,
risk evaluation, quantity produced,
distribution information, firms’ recall
strategy and a contact official as well as
requires firms to notify their direct
accounts of the recall and to provide
recipients with a ready means of
reporting to the recalling firm. Under
these portions of the collection of
information, the agency estimates it will
receive 2,166 responses annually for
each.
sroberts on PROD1PC70 with NOTICES
C. Recall Status Reports
Request that recalling firms provide
periodic status reports so FDA can
ascertain the progress of the recall. This
collection of information will generate
approximately 8,664 responses
annually.
VerDate Aug<31>2005
21:01 Oct 08, 2008
Jkt 217001
Dated: October 1, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E8–23910 Filed 10–8–08; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–N–0038]
Science Board to the Food and Drug
Administration; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Science Board to
the Food and Drug Administration
(Science Board).
General Function of the Committee:
The Science Board provides advice
primarily to the Commissioner of Food
and Drugs and other appropriate
officials on specific complex and
technical issues as well as emerging
issues within the scientific community
in industry and academia. Additionally,
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
the Science Board provides advice to
the agency on keeping pace with
technical and scientific evolutions in
the fields of regulatory science, on
formulating an appropriate research
agenda, and on upgrading its scientific
and research facilities to keep pace with
these changes. It will also provide the
means for critical review of agency
sponsored intramural and extramural
scientific research programs.
Date and Time: The meeting will be
held on Friday, October 31, 2008, from
8 a.m. to 3:30 p.m.
Location: Hilton, Washington DC
North/Gaithersburg Hilton, 620 Perry
Pkwy., Gaithersburg, MD 20877.
˜
Contact Person: Carlos Pena, Office of
the Commissioner, Food and Drug
Administration (HF–33), 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
˜
6687, carlos.pena@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512603. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: The Science Board will hear
about and discuss a review of the draft
assessment of Bisphenol A (BPA) for use
in food contact applications by the
E:\FR\FM\09OCN1.SGM
09OCN1
Agencies
[Federal Register Volume 73, Number 197 (Thursday, October 9, 2008)]
[Notices]
[Pages 59633-59634]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-23910]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2008-N-0314]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Recall Regulations
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by
November 10, 2008.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-6974, or e-mailed to baguilar@omb.eop.gov. All comments
should be identified with the OMB control number 0910-0249. Also
include the FDA docket number found in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT: Elizabeth Berbakos, Office of
Information Management (HFA-710), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-796-3792.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
FDA Recall Regulations--21 CFR Part 7--(OMB Control Number 0910-0249--
Extension)
Section 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
371) and part 7, subpart C (21 CFR part 7, subpart C), set forth the
recall regulations (guidelines) and provide guidance to manufacturers
on recall responsibilities. The guidelines apply to all FDA regulated
products (i.e., food, including animal feed; drugs, including animal
drugs; medical devices, including in vitro diagnostic products;
cosmetics; and biological products intended for human use). These
responsibilities include: (1) developing a recall strategy that
requires time by the firm to determine the actions or procedures
required to manage the recall (Sec. 7.42); (2) providing FDA with
complete details of the recall including reason(s) for the removal or
correction, risk evaluation, quantity produced, distribution
information, firm's recall strategy, a copy of any recall
communication(s), and a contact official (Sec. 7.46); (3) notifying
direct accounts of the recall, providing guidance regarding further
distribution, giving instructions as to what to do with the product,
providing recipients with a ready means of reporting to the recalling
firm (Sec. 7.49); (4) submitting periodic status reports so that FDA
may assess the progress of the recall (status report information may be
determined by, among other things, evaluation return reply cards,
effectiveness checks, and product returns) (Sec. 7.53); and (5)
providing the opportunity for a firm to request in writing that FDA
terminate the recall (Sec. 7.55).
A search of the FDA database was performed to determine the number
of recalls that took place during fiscal year 2007. The resulting
number of recalls from this database search (2,166) is used in
estimating the current annual reporting burden for this report. FDA
[[Page 59634]]
estimates the total annual industry burden to collect and provide the
previous information to 216,600 burden hours.
Table 1 of this document is a summary of the estimated annual
burden hours for recalling firms (manufacturers, processors, and
distributors) to comply with the voluntary reporting requirements of
FDA's recall regulations.
In the Federal Register of June 3, 2008 (73 FR 31696), FDA
published a 60-day notice requesting public comment on the information
collection provisions. No comments were received.
Recognizing that there may be a vast difference in the information
collection and reporting time involved in different recalls of FDA's
regulated products, FDA estimates on average the burden of collection
for recall information to be as follows:
Table 1.--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
21 CFR Section Respondents per Response Responses Response Total Hours
----------------------------------------------------------------------------------------------------------------
Recall 2,166 1 2,166 20 43,320
strategy 7.42
----------------------------------------------------------------------------------------------------------------
Firm initiated 2,166 1 2,166 30 64,980
recall and
recall
communication
s 7.46 and
7.49
----------------------------------------------------------------------------------------------------------------
Recall status 2,166 4 8,664 10 86,640
reports and
followup 7.53
----------------------------------------------------------------------------------------------------------------
Termination of 2,166 1 2,166 10 21,660
a recall
7.55(b)
----------------------------------------------------------------------------------------------------------------
Total 216,600
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
The annual reporting burdens are explained as follows:
Reporting
A. Recall Strategy
Request firms develop a recall strategy including provision for
public warnings and effectiveness checks. Under this portion of the
collection of information, the agency estimates it will receive 2,166
responses annually.
B. Firm Initiated Recall and Recall Communications
Request firms voluntarily remove or correct foods and drugs (human
or animal), cosmetics, medical devices, and biologicals to immediately
notify the appropriate FDA district office of such actions. The firm is
to provide complete details of the recall reason, risk evaluation,
quantity produced, distribution information, firms' recall strategy and
a contact official as well as requires firms to notify their direct
accounts of the recall and to provide recipients with a ready means of
reporting to the recalling firm. Under these portions of the collection
of information, the agency estimates it will receive 2,166 responses
annually for each.
C. Recall Status Reports
Request that recalling firms provide periodic status reports so FDA
can ascertain the progress of the recall. This collection of
information will generate approximately 8,664 responses annually.
D. Termination of a Recall
Provide the firms an opportunity to request in writing that FDA end
the recall. The agency estimates it will receive 2,166 responses
annually.
Dated: October 1, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-23910 Filed 10-8-08; 8:45 am]
BILLING CODE 4160-01-S